Wall Street analyst estimates for Clene Inc. (CLNN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS).
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.88 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.46 | ||
| 2026-08-14 | $-1.08 | $-0.37 | -193.5% |
| 2026-05-14 | $-0.69 | $-0.50 | -38.0% |
| 2026-03-12 | $-0.93 | $-0.74 | -25.7% |
| 2025-11-13 | $-0.85 | $-0.60 | -41.7% |
| 2025-08-14 | $-0.78 | $-0.49 | -59.2% |
| 2025-05-07 | $-0.09 | $-0.95 | +90.5% |
| 2025-03-24 | $-1.67 | $-1.21 | -38.0% |
Valuation Ratios
| Price / Book | -1.93 |
| EV / EBITDA | -3.38 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $206000 | $723000 | $473000 | $654000 | $342000 | $200000 |
| Cost of Revenue | 0 | 0 | $900000 | $65000 | $289000 | $26000 | $121000 | $70000 | $43000 |
| Gross Profit | 0 | 0 | -$900000 | $141000 | $434000 | $447000 | $533000 | $272000 | $157000 |
| Research & Development | 0 | $6.6M | $8.8M | $15.2M | $28.4M | $31.9M | $26.7M | $20.1M | $14.0M |
| Selling, General & Admin | $2387 | $323944 | $6.7M | $3.3M | $18.8M | $16.2M | $14.4M | $13.3M | $9.2M |
| Operating Expenses | $2387 | $323944 | $15.4M | $20.4M | $50.4M | $48.9M | $41.1M | $33.4M | $23.2M |
| Operating Income | -$2390 | -$323940 | -$16.3M | -$20.2M | -$50.0M | -$48.4M | -$40.5M | -$33.1M | -$23.1M |
| EBITDA | -$2390 | -$8.5M | -$15.2M | -$17.0M | -$8.3M | -$25.6M | -$43.2M | -$33.7M | -$22.0M |
| Interest Expense | 0 | 0 | $88000 | $950000 | $870000 | $3.3M | $4.6M | $4.1M | $2.7M |
| Pre-tax Income | -$2387 | $19429 | -$16.2M | -$18.9M | -$10.2M | -$29.9M | -$49.5M | -$39.4M | -$26.2M |
| Income Tax | 0 | 0 | 0 | $406000 | -$428000 | 0 | 0 | 0 | 0 |
| Net Income | -$2387 | -$277311 | -$16.2M | -$19.3M | -$9.7M | -$29.9M | -$49.5M | -$39.4M | -$26.2M |
| EPS | $-0.00 | $-0.09 | $-4.69 | $-5.51 | $-3.16 | $-4.69 | $-9.43 | $-5.67 | $-2.65 |
| EPS (Diluted) | $-0.00 | $-0.09 | $-4.69 | $-5.51 | $-3.16 | $-4.69 | $-9.43 | $-5.67 | $-2.65 |
| Shares Outstanding (Diluted) | $3.1M | $3.1M | $3.5M | $3.5M | $3.1M | $3.3M | $5.2M | $7.0M | $9.9M |
Price
| Price | $3.86 |
| Market Cap | $49M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CNTB · CNTX · COYA · MGNX · ORMP · OVID · PLRX
Explore sector: Healthcare · Biotechnology
More sections of CLNN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks